Short answer
Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on October 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). CFO Richard Lindahl departs December 31, 2026, then advises through March 31, 2027, supporting 2026 Form 10-K preparation.
Emergent BioSolutions Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Richard Lindahl departs December 31, 2026, then advises through March 31, 2027, supporting 2026 Form 10-K preparation
- Treasurer Frank Vargo becomes Interim CFO and principal financial and accounting officer January 1, 2027
- Vargo retains $328,000 base salary plus $3,850 per pay period interim compensation
- Leadership transition creates near-term execution risk, though internal succession and Lindahl’s advisory period support continuity
Item EX-99.1 · Exhibit EX-99.1
- CFO Richard S. Lindahl retires December 31, 2026 after nearly nine years at Emergent
- Treasurer Frank Vargo becomes interim CFO January 1, 2027, signaling internal succession and near-term continuity
- Lindahl remains senior executive advisor through March 31, 2027, supporting transition and reducing execution risk
- CFO change occurs during Emergent’s multi-year transformation plan, making financial discipline and strategy continuity key investor watchpoints
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Emergent BioSolutions Inc. 8-K filings
Get the next EBS 8-K as it lands
Follow EBS for push alerts, or ask the research agent what this filing means.